Caris Life Sciences, Inc. CAI
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 151.37% | -- | -- | -- | -- |
| Total Depreciation and Amortization | -17.85% | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -72.71% | -- | -- | -- | -- |
| Total Other Non-Cash Items | -15.67% | -- | -- | -- | -- |
| Change in Net Operating Assets | -861.81% | -- | -- | -- | -- |
| Cash from Operations | 15,463.92% | -- | -- | -- | -- |
| Capital Expenditure | -308.45% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1,052.26% | -- | -- | -- | -- |
| Total Debt Issued | 1,312.17% | -- | -- | -- | -- |
| Total Debt Repaid | -461,798.86% | -- | -- | -- | -- |
| Issuance of Common Stock | -93.83% | -- | -- | -- | -- |
| Repurchase of Common Stock | -104.06% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -100.00% | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 24.44% | -- | -- | -- | -- |
| Cash from Financing | -102.79% | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -212.66% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -113.86% | -- | -- | -- | -- |